Johnson & Johnson will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation’s opioid epidemic.

Eight drug companies urged a federal appeals court to disqualify the judge overseeing nationwide opioid litigation, in a last-ditch effort to avoid having him preside over a landmark trial.

In the wake of the discovery that some Zantac products may contain a carcinogen contaminant due to the manufacturing process, drug store retailers removed the antacid from shelves.

Walgreens Boots Alliance Inc. plans to close about 200 U.S. stores and expects to record related pre-tax charges of between $1.9 billion and $2.4 billion.

The Trump administration scrapped a proposal for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients.

Walgreens Boots Alliance Inc. shares fell 12 percent after the company cut the drug retailer’s 2019 earnings growth forecast and reported lower-than-expected quarterly profit in the face of stubbornly low generic drug prices in a crowded market.

Merix Pharmaceutical Corp. announced the company’s proprietary botanical extract formula VIRACEA was found to be highly active against HSV-1 and HSV-2 in laboratory testing.